Kuros Biosciences AG (KURN.SW)
CHF 20.5
(1.23%)
CHF 20.5
(1.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8.69 Million CHF | 60.77% |
| 2022 | -22.15 Million CHF | 16.33% |
| 2021 | -26.47 Million CHF | -1.65% |
| 2020 | -26.04 Million CHF | -41.46% |
| 2019 | -18.41 Million CHF | -0.44% |
| 2018 | -18.33 Million CHF | -9.96% |
| 2017 | -16.67 Million CHF | -34.8% |
| 2016 | -12.36 Million CHF | -872.1% |
| 2015 | 1.6 Million CHF | -92.24% |
| 2014 | 20.65 Million CHF | 240.72% |
| 2013 | -14.67 Million CHF | -0.08% |
| 2012 | -14.66 Million CHF | -231.27% |
| 2011 | 11.17 Million CHF | 112.54% |
| 2010 | 5.25 Million CHF | -82.98% |
| 2009 | 30.89 Million CHF | 50.23% |
| 2008 | 20.56 Million CHF | 33.9% |
| 2007 | 15.35 Million CHF | 293.69% |
| 2006 | -7.92 Million CHF | 30.87% |
| 2005 | -11.46 Million CHF | 45.47% |
| 2004 | -21.03 Million CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -8.7 Million CHF | 0.0% |
| 2023 Q1 | -14.57 Million CHF | 34.22% |
| 2023 Q2 | -13.99 Million CHF | 3.97% |
| 2023 FY | -8.69 Million CHF | 60.77% |
| 2023 Q4 | -8.69 Million CHF | 31.27% |
| 2023 Q3 | -12.64 Million CHF | 9.65% |
| 2022 Q3 | -22.56 Million CHF | -15.04% |
| 2022 Q4 | -22.15 Million CHF | 1.84% |
| 2022 FY | -22.15 Million CHF | 16.33% |
| 2022 Q1 | -19.92 Million CHF | 24.75% |
| 2022 Q2 | -19.61 Million CHF | 1.55% |
| 2021 Q2 | -24.81 Million CHF | 1.23% |
| 2021 Q3 | -26.79 Million CHF | -7.97% |
| 2021 Q4 | -26.47 Million CHF | 1.18% |
| 2021 Q1 | -25.12 Million CHF | 3.54% |
| 2021 FY | -26.47 Million CHF | -1.65% |
| 2020 Q3 | -26.32 Million CHF | -107.9% |
| 2020 FY | -26.04 Million CHF | -41.46% |
| 2020 Q2 | -12.66 Million CHF | 2.1% |
| 2020 Q1 | -12.93 Million CHF | 29.75% |
| 2020 Q4 | -26.04 Million CHF | 1.06% |
| 2019 Q3 | -18.66 Million CHF | -93.53% |
| 2019 FY | -18.41 Million CHF | -0.44% |
| 2019 Q1 | -9.89 Million CHF | 46.06% |
| 2019 Q2 | -9.64 Million CHF | 2.51% |
| 2019 Q4 | -18.41 Million CHF | 1.32% |
| 2018 Q4 | -18.33 Million CHF | 0.0% |
| 2018 Q3 | -18.33 Million CHF | -89.99% |
| 2018 Q2 | -9.65 Million CHF | 0.0% |
| 2018 Q1 | -9.65 Million CHF | 42.12% |
| 2018 FY | -18.33 Million CHF | -9.96% |
| 2017 Q3 | -16.67 Million CHF | 22.15% |
| 2017 Q2 | -21.41 Million CHF | 0.0% |
| 2017 Q1 | -21.41 Million CHF | -73.15% |
| 2017 FY | -16.67 Million CHF | -34.8% |
| 2017 Q4 | -16.67 Million CHF | -0.0% |
| 2016 Q1 | -17.44 Million CHF | -1189.01% |
| 2016 Q4 | -12.36 Million CHF | 0.0% |
| 2016 FY | -12.36 Million CHF | -872.1% |
| 2016 Q3 | -12.36 Million CHF | 29.1% |
| 2016 Q2 | -17.44 Million CHF | 0.0% |
| 2015 FY | 1.6 Million CHF | -92.24% |
| 2015 Q4 | 1.6 Million CHF | 113.08% |
| 2015 Q3 | -12.24 Million CHF | -466.11% |
| 2015 Q2 | -2.16 Million CHF | 0.0% |
| 2014 Q2 | 12.94 Million CHF | 0.0% |
| 2014 FY | 20.65 Million CHF | 240.72% |
| 2014 Q4 | 20.65 Million CHF | 0.0% |
| 2013 Q1 | -8.94 Million CHF | 39.01% |
| 2013 FY | -14.67 Million CHF | -0.08% |
| 2013 Q4 | -14.67 Million CHF | -506.85% |
| 2013 Q3 | 3.6 Million CHF | 296.84% |
| 2013 Q2 | -1.83 Million CHF | 79.51% |
| 2012 Q4 | -14.66 Million CHF | 31.06% |
| 2012 Q3 | -21.27 Million CHF | 11.92% |
| 2012 Q1 | 1.45 Million CHF | -86.98% |
| 2012 Q2 | -24.15 Million CHF | -1760.0% |
| 2012 FY | -14.66 Million CHF | -231.27% |
| 2011 Q1 | 6.1 Million CHF | 16.05% |
| 2011 Q2 | 10.86 Million CHF | 78.15% |
| 2011 Q3 | 8.48 Million CHF | -21.92% |
| 2011 Q4 | 11.17 Million CHF | 31.66% |
| 2011 FY | 11.17 Million CHF | 112.54% |
| 2010 Q2 | 16.24 Million CHF | -52.09% |
| 2010 Q4 | 5.25 Million CHF | -73.91% |
| 2010 Q3 | 20.15 Million CHF | 24.02% |
| 2010 Q1 | 33.91 Million CHF | 9.77% |
| 2010 FY | 5.25 Million CHF | -82.98% |
| 2009 FY | 30.89 Million CHF | 50.23% |
| 2009 Q4 | 30.89 Million CHF | 0.0% |
| 2008 FY | 20.56 Million CHF | 33.9% |
| 2007 FY | 15.35 Million CHF | 293.69% |
| 2006 FY | -7.92 Million CHF | 30.87% |
| 2005 FY | -11.46 Million CHF | 45.47% |
| 2004 FY | -21.03 Million CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Addex Therapeutics Ltd | -3.52 Million CHF | -146.795% |
| BB Biotech AG | 304.39 Million CHF | 102.855% |
| Basilea Pharmaceutica AG | 116.11 Million CHF | 107.484% |
| Evolva Holding SA | -5.83 Million CHF | -48.835% |
| Idorsia Ltd | 1.05 Billion CHF | 100.821% |
| Molecular Partners AG | -183.23 Million CHF | 95.258% |
| Relief Therapeutics Holding AG | -10.24 Million CHF | 15.178% |
| Santhera Pharmaceuticals Holding AG | -5.3 Million CHF | -63.715% |